As some of you are probably aware, Genzyme has announced that, due to production and supply constraints, starting March 30,

2020AOn October 7-9, 2011, 150 Pompe patients and their families, scientists, doctors, and industry representatives from around the world gathered

Excerpt from August 30, 2010 press release . . . BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has

Hi All, The AMDA has been working with Pfizer on supporting some proposed legislation in California that is intended to

Genzyme would like to provide an update to the US Pompe community regarding the transition to commercial LumizymeTM (alglucosidase alfaA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More)

The AMDA is excited to announce a research grant opportunity for applicants who are involved in Pompe DiseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More research. This

The AMDA is excited to announce a research grant opportunity for applicants who are involved in Pompe DiseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More research. This

On June 6, 2011 the AMDA will host a webinar on Respiratory Muscle Strength Training in Pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More at 12:00pm